{"id":"W4413783187","doi":"10.1016/s2152-2650(25)01538-1","title":"ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Oncology; Internal medicine; Pediatrics; Leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002713214,0.0003307444,0.0004840412,0.0002755698,0.0002441076,0.0007948481,0.0003411583,0.0004521197,0.001792209],"category_scores_gemma":[0.0006660774,0.0001944247,0.0007411569,0.000593547,0.0002267042,0.0005511062,0.0005600968,0.0007407675,0.0002629809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006303861,"about_ca_system_score_gemma":0.0004163391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002727961,"about_ca_topic_score_gemma":0.004424638,"domain_scores_codex":[0.9997097,0.00004925379,0.00001972608,0.00006891869,0.00003637743,0.0001159854],"domain_scores_gemma":[0.9996479,0.00003716904,0.0001553249,0.00001987493,0.00001583569,0.000123997],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01910214,0.0002585453,0.9669043,0.00005211184,0.0005689609,0.0003373907,0.00008392682,0.0005856876,0.002627773,0.0001556137,0.0007380715,0.008585433],"study_design_scores_gemma":[0.0003620743,0.001518939,0.9948058,0.00001482685,0.0003916256,0.0005221638,0.0002172828,0.0006159914,0.0003299093,0.0001810419,0.001024184,0.00001626927],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998139,0.000484022,0.00004008187,0.00006839935,0.00001408229,0.000008168498,0.0004809407,0.000004194269,0.0007609908],"genre_scores_gemma":[0.9984576,0.0001658309,0.00002087228,0.00006598468,0.00002058699,0.000008307376,0.0009034361,0.000002762911,0.0003546285],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002727961,"threshold_uncertainty_score":0.005995572,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02242904538383347,"score_gpt":0.3368691806410551,"score_spread":0.3144401352572216,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}